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Abstract
 2q .Calpain Ca -activated cysteine protease induced proteolysis has been suggested to play a role in myoblast fusion. We
 .previously found that calpastatin the endogenous inhibitor of calpain diminishes markedly in myoblasts during myoblast
differentiation just prior to the start of fusion, allowing Ca2q-induced calpain activation at that stage. Here, we show that a
limited degradation of some proteins occurs within the myoblasts undergoing fusion, but not in proliferating myoblasts. The
protein degradation is observed at the stage when calpastatin is low. Protein degradation within the myoblasts and myoblast
fusion are inhibited by EGTA, by the cysteine protease inhibitors calpeptin and E-64d and by calpastatin. The degradation
appears to be selective for certain myoblast proteins. Integrin b 1 subunit, talin and b-tropomyosin are degraded in the
fusing myoblasts, whereas a-actinin, b-tubulin and a-tropomyosin are not. A similar pattern of degradation is observed in
lysates of proliferating myoblasts when Ca2q and excess calpain are added, a degradation that is inhibited by calpastatin.
The results support the notion that degradation of certain proteins is required for myoblast fusion and that calpain
participates in the fusion-associated protein degradation. Participation of calpain is made possible by a change in
calpainrcalpastatin ratio, i.e., by a diminution in calpastatin level from a high level in the proliferating myoblasts to a low
level in the differentiating myoblasts. Degradation of certain proteins, known to be responsible for the stability of the
membrane–skeleton organization and for the interaction of the cell with the extracellular matrix, would allow destabilization
of the membrane and the creation of membrane fusion-potent regions. q 1998 Elsevier Science B.V.
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1. Introduction
During development, myoblasts cease to divide,
differentiate and fuse to form multinucleated muscle
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cells. Myoblast differentiation and fusion to multinu-
cleated myotubes can be achieved in myoblast cul-
w xtures 1,2 . Myoblast cultures provide a convenient
system for studying some of the steps and factors
involved in muscle formation, with implications for
cell membrane fusion processes in general. Studies
on the morphological aspects of cell fusion have
delineated multiple steps in a variety of fusion pro-
cesses, involving cell–cell alignment, tight apposition
of the cell membranes and formation of particle-free,
w xphospholipid-rich membrane domains 3–9 . The ac-
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tual fusion first involves small areas, where the
breakdown of the apposed membranes occurs, with
the establishment of small regions of cytoplasmic
w xcontinuity between the fusing cells 3–9 .
Proliferating myoblasts have well organized mem-
brane and skeletal framework, which become tem-
porarily destabilized in differentiating, fusing my-
w xoblasts 7 . It has been proposed that membrane
protein degradation contributes to the disorganization
of cell membrane and cytoskeleton in fusing cells,
including fusing myoblasts, and that calpain intra-
2q .cellular, Ca -dependent cysteine protease is in-
volved in the fusion-associated protein degradation
w x10–15 . Myoblast fusion has been shown to be
inhibited by cell penetrating cysteine protease in-
w xhibitors 13–17 .
Calpain is present in a wide variety of cells, along
w xwith its endogenous inhibitor, calpastatin 18–20 .
Using red cells as models for cell membrane fusion,
we previously found that calpain-induced degradation
of certain membrane proteins was a prerequisite for
red cell membrane fusion and that the cell fusibility
depended on the ratio of the red cell calpain to
w xcalpastatin 21,22 . We found that in rat L8 my-
oblasts, the level of calpain as estimated by antibod-
.ies did not change during myoblast differentiation
and fusion, but that a transient diminution of calpas-
w x 2qtatin occurred in fusing myoblasts 16 . Using Ca
and the artificial substrate casein in a standard assay
for the estimation of calpain activity, we observed
degradation of casein when it was added to extracts
of fusing myoblasts at the stage when calpastatin
level was low, but not when added to extracts of
w xproliferating cells 16 . These results indicated that
the diminution in calpastatin allowed the activation of
w xcalpain in the fusing myoblasts 16 .
In order to find out whether degradation of en-
dogenous proteins occurs within these myoblasts, we
studied fusing and non-fusing myoblasts, using anti-
bodies to several membrane and cytoskeletal proteins.
Here we show that a limited degradation of some
membrane and cytoskeletal proteins occurs within
myoblasts undergoing fusion. The endogenous pro-
tein degradation is observed at the stage when calpas-
tatin is low and is inhibited by calpain inhibitors. The
degradation appears to be selective for certain my-
oblast proteins. A similar pattern of degradation is
observed in lysates of proliferating myoblasts when
Ca2q and excess calpain are added, a degradation
that is inhibited by calpastatin. The overall results
support the notion that a degradation of certain cyto-
skeletal and membrane proteins participates in the
events which lead to destabilization of the membrane
and the creation of membrane fusion-potent regions
and that calpain is involved in the fusion-associated
protein degradation.
2. Materials and methods
2.1. Myoblast cultures
Rat myoblast L8 cell line was obtained from Dr.
D. Yaffe The Weizmann Institute of Science, Re-
.hovot, Israel . The cells were cultured and induced to
w xdifferentiate, as described previously 17 . Briefly,
myoblasts were grown in Waymouth medium in the
presence of 15% F.C.S., 1% antibiotics and 1%
 .glutamine growth medium . When the number of
cells reached about 50% confluency, the medium was
changed to DMEM, supplemented by 2% horse
serum, 1% antibiotics, 1% glutamine and four units
 .of insulinr100 ml medium fusion medium . The
fusion medium was replaced every 48 h. Inhibitors
 .used were EGTA, E-64d Sigma, USA , calpeptin
 w xRef. 14 , a gift from Dr. T. Tsujinaka, Osaka Uni-
.versity Medical School, Suita, Osaka, Japan and
human recombinant calpastatin M.W. 14 000, Cal-
.biochem, USA . Each of the reagents used was added
to the fusion medium, then replenished every 48 h,
along with the replacement of the fusion medium.
The inhibitors were used at final concentrations of
1.5 mM EGTA added to fusion medium containing
. 1.8 mM CaCl , 30 mM E-64d diluted from a stock2
.solution of 15 mM in DMSO , 15–25 mM calpeptin
diluted from a stock solution of 10 mM in DMSO
w x.14 , or 0.04–0.08 mgrml of medium of recombi-
nant calpastatin. For the estimation of the extent of
fusion, the cells were washed, fixed and stained with
Giemsa. The percent of fused cells was estimated by
counting nuclei in myotubesrtotal of 400–500 nu-
clei.
2.2. Preparation of cell extracts
The cells in the Petri dishes were washed with
PBS, then harvested with PBS containing 5 mM
( )S. Barnoy et al.rBiochimica et Biophysica Acta 1402 1998 52–6054
EDTA. Cells were centrifuged, then lysed in a solu-
tion containing 20 mM Tris–HCl, pH 7.4, 150 mM
NaCl, 1% Triton X-100, 2.5 mM EDTA, 2.5 mM
EGTA, 0.1 mM p-aminoethylbenzenesulfonyl fluo-
 .ride AEBSF and 10 mg of aprotoninrml solution.
Samples were kept in ice for 30 min, then centrifuged
at 8000=g. Protein concentration in the supernatants
w xwas determined by the method of Lowry et al. 23 .
Aliquots of supernatants were mixed with Laemmli
sample buffer, heated and proteins separated by
SDS-PAGE. Some gels were then stained with
Coomassie blue. Other gels were analysed by im-
munoblotting.
2.3. Effects of calpain added to cell lysates
Cells were grown in Waymouth medium until half
confluence, then harvested and lysed as described
above. Aliquots of lysates were mixed with a buffer
solution of 20 mM Tris–HCl, pH 7.4, 150 mM NaCl,
0.1 mM AEBSF one volume of lysate containing 50
mg of myoblast protein mixed with four volumes of
.buffer . The samples were incubated for 15 min at
308C in the presence of 2.0 mM CaCl , 0.5 mM2
 .dithiothreitol DTT , with and without added calpain
0.5–1.0 units of calpain purified from human
w x. erythrocytes 22 and calpastatin 1.0–2.0 units of
w x.calpastatin purified from human erythrocytes 22 .
The samples were then mixed with sample buffer, as
described above, electrophoresed, some gels stained
with Coomassie blue and others analysed by
immunoblotting.
2.4. Immunoblotting procedures
SDS-PAGE was carried out according to standard
procedures, using 10% acrylamide. Samples contain-
ing 40 mg of myoblast proteins were electrophoresed,
then transferred to nitrocellulose membranes Gel-
.man . Blocking was carried out in a solution contain-
ing 20 mM Tris–HCl, 150 mM NaCl, 5% low fat dry
milk, 0.05% Tween-20 and 0.02% sodium azide. The
membranes were then incubated overnight with the
primary antibodies. Antibodies used were: antitalin
monoclonal antibody against the 230 kDa whole
 .molecule Sigma , diluted 1:4000; antitalin poly-
clonal antibody against the 200 kDa calpain-gener-
 w xated talin fragment Ref. 24 , a gift from Dr. M.
Inomata, Tokyo Metropolitan Institute of Gerontol-
.ogy, Japan , diluted 1:300; antiintegrin polyclonal
antibody against the 39 amino acids at the C-terminal
cytoplasmic domain of integrin b 1 a gift from Dr.
.R. Hynes, M.I.T., Boston, USA , diluted 1:1000;
antitropomyosin and anti b-tubulin monoclonal anti-
 .bodies Sigma, USA , diluted 1:2000; anti a-actinin
 .polyclonal antibody Bio Makor , diluted 1:1000.
Following incubation with the primary antibodies, the
membranes were washed four times with the block-
 .ing buffer lacking azide and incubated for 1 h with
the appropriate peroxidase-conjugated secondary an-
wtibodies rabbit anti-mouse antibody for the mono-
 .clonal antibodies Amersham , diluted 1:20 000 and
goat anti-rabbit antibody for the primary polyclonal
 . xantibodies Sigma , diluted 1:60 000 . Membranes
were then washed exhaustively in 20 mM Tris–HCl,
150 mM NaCl, 0.05% Tween-20. Detection of bands
was carried out with the ECL immunoblotting detec-
 .tion system ECL, Amersham .
3. Results
3.1. Effects of inhibitors on myoblast growth and
myoblast fusion
Myoblasts, induced to differentiate by changing
the growth medium to fusion medium, became con-
fluent at about 24–36 h after the change of medium.
Alignment of myoblasts and start of fusion was ob-
served at about 72–96 h, followed by fusion to
multinucleated myotubes. About 60–80% of the my-
oblasts were fused at 120–144 h under the experi-
w xmental conditions used, as previously described 17
 .Fig. 1 . Calpastatin inhibited myoblast fusion, with
about 5–10% of cell fusion observed following the
addition of 0.05 mg of recombinant calpastatinrml of
 .medium Fig. 1 . About 5% of fusion was obtained
 .by using 30 mM of E-64d Fig. 1 or 25 mM
calpeptin cell penetrating cysteine protease in-
.hibitors . EGTA inhibited fusion to a similar extent
and, under the conditions used, did not affect the cell
viability and allowed cell division to continue to
 .confluency not shown .
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3.2. Degradation of membrane proteins in fusing
myoblasts and effects of inhibitors
Cell extracts were prepared from myoblasts cul-
tured in growth medium and from cultured cells
following the change to fusion medium, in the pres-
ence and absence of inhibitors. Aliquots of myoblast
extracts were electrophoresed, stained by Coomassie
blue or analysed by immunoblotting, as described in
Section 2. No gross changes in the overall protein
 .profiles Coomassie blue staining were observed in
the myoblasts during differentiation and fusion and
the profiles of the inhibited, non-fusing myoblasts
 .were similar to those of control cells Fig. 2A .
Immmunoblotting analysis showed degradation of
some proteins in myoblasts undergoing fusion. b-
Tropomyosin was found to be degraded to a fraction
 .of lower molecular weight Fig. 2B . Similarly, a
partial talin degradation to lower molecular weight
fraction was observed in the myoblasts undergoing
fusion, as shown by antibody which recognizes both
 .undegraded and degraded talin Fig. 2C . In addition,
using an antibody which selectively recognizes talin
fragment generated by calpain-induced talin degrada-
w xtion 24 , a degraded talin fraction was identified in
 .the fusing myoblasts Fig. 2C . Degradation of b 1
 .integrin was also observed in these cells Fig. 2D .
No degradation of these proteins occurred in my-
oblasts prevented from fusing by any of the inhibitors
 .used Fig. 2B,C,D . On the other hand, a-tropomyo-
 .  . sin Fig. 2B , tubulin Fig. 2E and a-actinin Fig.
.2F did not appear to be degraded in myoblasts
undergoing fusion, nor were there any effects of the
inhibitors on the appearance of these proteins.
3.3. Effects of calpain and of calpastatin added to
myoblast lysates
Myoblast lysates, prepared from proliferating my-
 .oblasts myoblasts cultured in growth medium , were
incubated in the presence of Ca2q and DTT, with and
without added calpain and calpastatin, followed by
SDS-PAGE and immunoblotting, as described in Sec-
tion 2. As shown by Coomassie blue staining, incuba-
tion of myoblast lysate with added calpain resulted in
the degradation of some protein fractions, notably in
the region of high molecular weight protein fractions
above and below 190 kDa, around 100 kDa as well as
in the region of about 40–35 kDa fractions. The
addition of calpastatin in excess to the added calpain
 .led to inhibition of the protein degradation Fig. 3A .
Myoblast tropomyosin was degraded in these lysates
by the added calpain, with b-tropomyosin more sus-
ceptible than a-tropomyosin to degradation; the
degradation was inhibited by the addition of excess
 .calpastatin Fig. 3B . Similarly, talin was degraded
by calpain, with the degraded talin fragment identi-
fied by the antibody specific against talin degraded
w xby calpain 24 ; no degradation of talin occurred in
 .the presence of calpastatin Fig. 3C . Integrin was
Fig. 1. Phase-contrast micrographs of rat L8 myoblasts. Myoblasts shown at 120 h after change of growth medium to fusion medium
without and with the addition of 0.05 mg recombinant calpastatinrml of medium or with 30 mM E-64d. The inhibitors were replaced
 .every 2 days, along with the replacement of fusion medium for details, see Section 2 .
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also degraded by calpain and the degradation was
 .inhibited by added calpastatin Fig. 3D . In contrast,
b-tubulin was not degraded under these conditions
 .Fig. 3E . a-Actinin in myoblast lysate was also not
 .degraded by calpain not shown . Thus, the sensitiv-
ity of the proteins in lysates of proliferating my-
 .  .Fig. 2. SDS-PAGE and immunoblotting of myoblast proteins for details, see Section 2 . A Coomassie blue stained profiles of myoblast
 .proteins. Myoblast extracts were prepared at the time of change of growth medium to fusion medium 0 h , and at 48, 96, 120 and 144 h;
 .cell extracts were prepared of control, fusing cells and of non-fusing myoblasts inhibited by 20 mM calpeptin. B Immunoblotting for the
 .identification of a- and b-tropomyosin in control, fusing myoblasts and in non-fusing cells inhibited by 1.5 mM EGTA. C
Immunoblotting for the identification of talin in control, fusing myoblasts and in non-fusing cells inhibited by 0.05 mg recombinant
calpastatinrml of medium. Left, immunoblotting with anti-talin antibody, which recognizes undegraded and degraded talin; right,
 .immunoblotting with antibody specific to calpain-induced degradation of talin. D Immunoblotting for the identification of b 1 integrin
 .in control, fusing myoblasts and in non-fusing cells inhibited by 30 mM E-64d. E Immunoblotting for the identification of b-tubulin in
 .control, fusing myoblasts and in non-fusing cells inhibited by 1.5 mM EGTA. F Immunoblotting for the identification of a-actinin in
control, fusing myoblasts and in non-fusing cells inhibited by 20 mM calpeptin.
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Fig. 3. SDS-PAGE and immunoblotting of lysates of proliferating myoblasts. The lysates were treated with and without calpain and
 .  .  .calpastatin for details, see Section 2 . A Coomassie blue stained profiles of proteins in myoblast lysates. B Immunoblotting for the
 .identification of a- and b-tropomyosin in the control and treated lysates. C Immunoblotting for the identification of talin and
calpain-induced talin degradation. Left, immunoblotting with anti-talin antibody, which recognizes undegraded and degraded talin; right,
 .immunoblotting with antibody specific to calpain-induced degradation of talin. D Immunoblotting for the identification of b 1 integrin
 .in the control and treated lysates. E Immunoblotting for the identification of b-tubulin in the control and treated lysates.
oblasts to degradation by added calpain appeared to
parallel the behavior of these proteins in the intact
myoblasts undergoing fusion.
4. Discussion
Fusing myoblasts have been shown to temporarily
develop numerous lacunae, which appear to be re-
gions of the membrane lipid bilayer devoid of some
w xsurface proteins 7 . The formation of the lacunae is
not due to a drastic loss of membrane proteins, but to
destabilization and disorganization of the myoblast
w xskeletal network during fusion 7 and may corre-
spond to the lipid-rich domains, relatively free of
w xproteins, observed in fusing myoblasts 5,7 . Cell
shape stabilization, interaction with other cells and
 .with extracellular matrix ECM are controlled by
associations among the cytoskeletal proteins and by
proteins connecting the cytoskeleton to the plasma
w xmembrane 25 . Destabilization of the skeletal net-
work in the fusing myoblasts would result from
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disrupting the linkages between the cytoskeleton and
the plasma membrane.
We show here that integrin b 1 subunit, talin and
b-tropomyosin are degraded in the fusing myoblasts,
whereas a-actinin, b-tubulin and a-tropomyosin are
not. Integrins are a major family of heterodimeric cell
surface receptors, composed of various a and b
subunits, that mediate interactions of cells with the
w xECM and with other cells 25–27 . Integrins mediate
bidirectional transfer of information across the plasma
membrane by linking extracellular proteins to cyto-
skeleton proteins and actin filaments, with some
shown to bind to cytoskeletal proteins through the
w xintegrin b 1 cytoplasmic domain 25–27 . Degrada-
tion of the cytoplasmic domain of integrin b 1 sub-
unit may thus modulate the attachment of the cell to
the ECM and the organization of the cytoskeleton.
Disruption of membrane–cytoskeleton linkages
would also result from degradation of linker proteins,
such as talin. Talin is required for the stability of the
adhesion plaques, where communications between
the cytoskeleton and the ECM are maintained, and
cleavage of talin is associated with detachment of
w xcultured cells from the ECM 28 . Both talin and
a-actinin, in addition to linking actin filaments to
integrin, may also bind directly to acidic phospho-
w xlipids 25 . Disruption of such binding may play a
part in the altered phospholipid organization and
redistribution of the bilayer phospholipids, a redistri-
bution that contributes to the fusion competency of
w xthe myoblasts 29 . In addition to the myoblast pro-
teins studied here, the actin-binding protein filamin
and the intermediate filament desmin have also been
w xshown to be degraded in fusing myoblasts 30,31 .
The degradation of these proteins and degradation of
actin-stabilizing proteins such as b-tropomyosin,
would add to the skeletal disorganization and to
freeing of membrane domains from the restraints of
linkage to the cell cytoskeleton.
The inhibition of protein degradation by cysteine
protease inhibitors, including the specific calpain in-
hibitor calpastatin, is consistent with the notion that
calpain is involved in protein degradation in fusing
myoblasts. Support for calpain involvement in protein
degradation in the fusing myoblasts is also provided
by the identification of a calpain-specific talin frag-
ment, using an antibody which selectively recognizes
a 200 kDa fragment when talin is digested by calpain
w x24 and the inhibition of that degradation by calpas-
tatin. The fact that intracellular protein degradation is
inhibited by the calpastatin added to intact differenti-
ating myoblasts indicates that calpastatin is being
taken up by these cells, though the mechanism for the
uptake is not known. Since calpastatin is known to be
w xsensitive to degradation by some enzymes 19,20 , it
 .may be taken up as active fragment s rather than as
a large molecule. The mode of uptake waits further
study.
The results shown here indicate that the protein
degradation in the fusing myoblasts is not a general-
ized protein breakdown. The fact that talin is de-
graded in the fusing myoblasts but a-actinin is not
points to the selectivity of protein degradation during
myoblast differentiation. Talin is a physiological sub-
w xstrate for calpain during platelet aggregation 24,33
and is the preferred substrate for calpain among the
w xadhesion plaque proteins 32 . Selectivity of protein
degradation by calpain has been shown in some cell
w xtypes 28,32 and has been suggested to be due to an
association of the protease with a substrate in specific
w xlocations such as the adhesion plaques 28,32 . It
should be pointed out that even an excess of calpain
added in vitro to cell lysates does not cause a general
protein degradation but only degradation of some
proteins. Thus, the degradation of the particular pro-
teins observed in the fusing myoblasts but not in the
proliferating cells appears not to be due to changes in
substrate properties, since their degradation is possi-
ble when the endogenous high level of calpastatin in
proliferating myoblasts is overcome by excess cal-
pain added to Ca2q-containing lysates of these cells.
Calpain activation, made possible by the diminu-
w xtion in calpastatin in fusing myoblasts 16,17 , re-
quires Ca2q. Cytosolic Ca2q has been shown to be
w xelevated during myoblast fusion 34 . Calpain activa-
tion is generally considered to be enhanced by its
translocation to the membrane and by association
w xwith phospholipids 20,35–37 . It is not clear whether
m-calpain or m-calpain is mostly involved in my-
oblast fusion. Since m-calpain can activate m-calpain
w x38 , it is possible that both are involved. Cytoplas-
mic unilamellar, particle-free vesicles have been de-
scribed to appear in cultured, fusing myoblasts in
w xclose proximity to the plasma membrane 5 . It has
been proposed that the interaction of the cytoplasmic
vesicles with the plasma membrane initiates the
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membrane destabilization and the formation of the
w xfusion domains 5 . Prefusion complexes, consisting
of intracellular vesicles, that align and pair across
apposed myoblast membranes with vesicles in the
other cell, have been shown to form in myoblasts
w xfusing in vivo 9 . The composition of the vesicles is
not known at present. It would be of interest to study
whether they play a role in protein degradation in the
fusing myoblasts. It should also be noted that in
addition to being involved in protein degradation,
calpain may affect membrane–cytoplasmic interac-
tions indirectly. One such possibility is calpain-in-
duced activation of PKC, leading to phosphorylation
of proteins such as the myristoylated alanine-rich
 .protein kinase C substrate MARCKS and resulting
in the dissociation of the protein from the membrane
w xand altered membrane organization 39,40 .
5. Conclusion
Degradation of certain proteins, known to be re-
sponsible for the stability of the membrane–skeleton
organization and for the interaction of the cell with
the ECM, appears to be required for myoblast fusion.
Data presented here support the notion that calpain
participates in the fusion-associated protein degrada-
tion. The participation of calpain in the fusion pro-
cess does not exclude the involvement of other pro-
w xteases, such as cathepsin B, in myoblast fusion 41 .
In addition to the participation of the calpain–
calpastatin system in myoblast fusion, calpain-in-
duced protein degradation, controlled by calpastatin,
may be involved in other cell membrane sealing and
w xrepair processes 42,43 .
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